Beyzaee AM, Rokni GR, Patil A, et al. - In this investigation, the researchers sought to review the literature on the treatment, management and subsequent consequences of rituximab as a treatment for pemphigus vulgaris (PV) in the current coronavirus disease (COVID‐19) pandemic era. “PubMed” and “Google Scholar” database have been systematically searched for retrieving all articles related to anti‐CD20 therapy in PV and COVID‐19 published up to July 14, 2020. There is limited evidence for the treatment of PV patients with rituximab during the COVID‐19 pandemic. Until sufficient evidence or guidance for pemphigus and COVID‐19 treatment is available, the authors propose caution against starting rituximab in patients with pemphigus due to reported adverse outcomes.